-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Statistics show that as of December 12, 75 biomedical companies have been gathered on the Sci-tech Innovation Board, accounting for 20.
43% of the listed companies on the Sci-Tech Innovation Board
.
Among them, in 2021 alone, there will be 33 biomedical companies listed, the number is much higher than 28 in 2020 and 14 in 2019
.
It is worth mentioning that in terms of market value, 13 companies have a market value of more than 10 billion yuan
.
For example, Novartis, the leading bio-reagent marketed on November 15th, has a higher market value
.
It is understood that Novartis Biosciences is a biotechnology company that conducts technology research and product development around functional proteins and polymer organic materials such as enzymes, antigens, antibodies, etc.
Relying on the key common technology platform established by itself, it has successively entered biological reagents.
In the field of in vitro diagnostics business, the research and development of antibody drugs is ongoing
.
Its opening price was 74 yuan, an increase of 34.
5% from the issue price; since then, the stock price has risen, reaching 46.
273 billion yuan at its peak
.
In addition, Dizhe Pharmaceutical, an innovation-driven biomedical company that recently landed on the Science and Technology Innovation Board, has a market value of more than 10 billion yuan
.
Specifically, on December 10, Dizhe Pharmaceutical successfully landed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, raising a total of 2.
09 billion yuan
.
As of the close on December 10, Dizhe Pharmaceutical reported 41.
10 yuan per share
.
However, since the issue was broken on the first day of listing, based on the closing price, Dizhe Pharmaceutical's market value was only 16.
44 billion yuan
.
However, from its official establishment in October 2017 to the successful listing of the IPO on the Sci-tech Innovation Board in December 2021, Dizhe Pharmaceutical only took 4 years to see that its rapid growth rate is still very eye-catching
.
On the whole, the biopharmaceutical companies that have landed on the Sci-tech Innovation Board this year involve chemical preparations, in vitro diagnostics, medical equipment, vaccines and other subdivisions.
They also have certain competitive advantages in their respective subdivisions; therefore, they have landed on the capital market.
After that, it also received continuous attention from investors
.
Nuovazan has recently received surveys from 97 institutions, including well-known institutions such as Jinglin, Gaoyi, Qingchi, and Fuguo.
.
The industry believes that, as a research and development-driven industry, the pharmaceutical and biological industry conforms to the positioning attributes of the science and technology innovation board
.
Compared with traditional pharmaceutical companies, the future layout of innovative pharmaceutical companies will be recognized by the market and their valuations will become higher and higher
.
However, it should be noted that there are not a few biopharmaceutical companies that have succumbed to the Sci-tech Innovation Board IPO this year
.
Statistics show that nearly 20 biomedical companies have terminated their IPOs from January to November 2021, which is higher than the sum of the previous two years
.
For example, on September 30, the Shanghai Stock Exchange stated in an announcement that due to the issuer's withdrawal of the issuance and listing application or the withdrawal of the sponsor's sponsorship, the Shanghai Stock Exchange decided to terminate the review of Suzhou Jingyun Pharmaceutical Technology Co.
, Ltd.
's initial public offering and listing on the Science and Technology Innovation Board
.
According to data, the Shanghai Stock Exchange accepted the IPO application of Jingyun Pharmaceutical's Science and Technology Innovation Board in June 2020
.
In March 2021, Jingyun Medicine attended the meeting, but it was finally postponed for deliberation
.
In addition, Tasly Biology, Aopu Biology, Beijing Tianguangshi Biology, Eteng Jingang, etc.
also reported the termination of the IPO of the Science and Technology Innovation Board
.
According to the combing point of view, the main reasons for these companies to terminate IPOs are as follows: or the companies themselves do not meet the listing standards, and the previous declarations are only for arbitrage; or they are not optimistic about the trend after listing; or other may be exposed.
Problem
.
Analysis believes that, among them, lack of innovation and non-compliance with the requirements of science and technology may be the main reasons for the failure of the IPO
.
In fact, the Science and Technology Innovation Board has always regarded "hard technology" as its key support direction
.
Allowing unprofitable biopharmaceutical companies to open the door to listing can be said to be one of the important manifestations of the inclusiveness of the Sci-tech Innovation Board
.
From the current situation of pharmaceutical companies entering the science and technology innovation board, domestic biomedical companies need to continue to strengthen their innovation capabilities; at the same time, they also need to build more comprehensive competitiveness to deal with risks and challenges that come at any time, such as improving internal execution Ability, global resource integration capability, capital operation, etc.
to enhance corporate strength and competitiveness
.
43% of the listed companies on the Sci-Tech Innovation Board
.
Among them, in 2021 alone, there will be 33 biomedical companies listed, the number is much higher than 28 in 2020 and 14 in 2019
.
It is worth mentioning that in terms of market value, 13 companies have a market value of more than 10 billion yuan
.
For example, Novartis, the leading bio-reagent marketed on November 15th, has a higher market value
.
It is understood that Novartis Biosciences is a biotechnology company that conducts technology research and product development around functional proteins and polymer organic materials such as enzymes, antigens, antibodies, etc.
Relying on the key common technology platform established by itself, it has successively entered biological reagents.
In the field of in vitro diagnostics business, the research and development of antibody drugs is ongoing
.
Its opening price was 74 yuan, an increase of 34.
5% from the issue price; since then, the stock price has risen, reaching 46.
273 billion yuan at its peak
.
In addition, Dizhe Pharmaceutical, an innovation-driven biomedical company that recently landed on the Science and Technology Innovation Board, has a market value of more than 10 billion yuan
.
Specifically, on December 10, Dizhe Pharmaceutical successfully landed on the Science and Technology Innovation Board of the Shanghai Stock Exchange, raising a total of 2.
09 billion yuan
.
As of the close on December 10, Dizhe Pharmaceutical reported 41.
10 yuan per share
.
However, since the issue was broken on the first day of listing, based on the closing price, Dizhe Pharmaceutical's market value was only 16.
44 billion yuan
.
However, from its official establishment in October 2017 to the successful listing of the IPO on the Sci-tech Innovation Board in December 2021, Dizhe Pharmaceutical only took 4 years to see that its rapid growth rate is still very eye-catching
.
On the whole, the biopharmaceutical companies that have landed on the Sci-tech Innovation Board this year involve chemical preparations, in vitro diagnostics, medical equipment, vaccines and other subdivisions.
They also have certain competitive advantages in their respective subdivisions; therefore, they have landed on the capital market.
After that, it also received continuous attention from investors
.
Nuovazan has recently received surveys from 97 institutions, including well-known institutions such as Jinglin, Gaoyi, Qingchi, and Fuguo.
.
The industry believes that, as a research and development-driven industry, the pharmaceutical and biological industry conforms to the positioning attributes of the science and technology innovation board
.
Compared with traditional pharmaceutical companies, the future layout of innovative pharmaceutical companies will be recognized by the market and their valuations will become higher and higher
.
However, it should be noted that there are not a few biopharmaceutical companies that have succumbed to the Sci-tech Innovation Board IPO this year
.
Statistics show that nearly 20 biomedical companies have terminated their IPOs from January to November 2021, which is higher than the sum of the previous two years
.
For example, on September 30, the Shanghai Stock Exchange stated in an announcement that due to the issuer's withdrawal of the issuance and listing application or the withdrawal of the sponsor's sponsorship, the Shanghai Stock Exchange decided to terminate the review of Suzhou Jingyun Pharmaceutical Technology Co.
, Ltd.
's initial public offering and listing on the Science and Technology Innovation Board
.
According to data, the Shanghai Stock Exchange accepted the IPO application of Jingyun Pharmaceutical's Science and Technology Innovation Board in June 2020
.
In March 2021, Jingyun Medicine attended the meeting, but it was finally postponed for deliberation
.
In addition, Tasly Biology, Aopu Biology, Beijing Tianguangshi Biology, Eteng Jingang, etc.
also reported the termination of the IPO of the Science and Technology Innovation Board
.
According to the combing point of view, the main reasons for these companies to terminate IPOs are as follows: or the companies themselves do not meet the listing standards, and the previous declarations are only for arbitrage; or they are not optimistic about the trend after listing; or other may be exposed.
Problem
.
Analysis believes that, among them, lack of innovation and non-compliance with the requirements of science and technology may be the main reasons for the failure of the IPO
.
In fact, the Science and Technology Innovation Board has always regarded "hard technology" as its key support direction
.
Allowing unprofitable biopharmaceutical companies to open the door to listing can be said to be one of the important manifestations of the inclusiveness of the Sci-tech Innovation Board
.
From the current situation of pharmaceutical companies entering the science and technology innovation board, domestic biomedical companies need to continue to strengthen their innovation capabilities; at the same time, they also need to build more comprehensive competitiveness to deal with risks and challenges that come at any time, such as improving internal execution Ability, global resource integration capability, capital operation, etc.
to enhance corporate strength and competitiveness
.
